Back to discover

Protein / target

Baculoviral IAP repeat-containing protein 3

Encoded byBIRC3Q13489Homo sapiensSwiss-Prot
UniProt: Q13489Ensembl: ENSG00000023445HGNC: HGNC:591NCBI Gene: 330
Clinical-stage
Therapeutic maturity
1
Clinical candidates
12
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Ubiquitin-protein transferase

Strongest disease association

Crohn's Disease

Via encoding gene BIRC3 · Genetic evidence · score 0.66

Therapeutic position

Clinically advancing target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis.

View complete UniProt function annotation

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8

Subcellular location

CytoplasmNucleus
Domains and Gene Ontology detail (33)

Domains & features

CARD

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane
  • Cprotein-containing complex
  • Fcysteine-type endopeptidase inhibitor activity involved in apoptotic process
  • Fprotein-containing complex binding
  • Ftransferase activity
  • Fubiquitin protein ligase activity
  • Fubiquitin-protein transferase activity
  • Fzinc ion binding

604 aa · 68 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Apoptosis & cell deathUniProt · GOImmune signallingGOMetabolic enzyme activityGO
View supporting evidence

Apoptosis & cell death

  • ·Multi-functional protein which regulates not only caspases and apoptosis, but also modul…
  • ·cysteine-type endopeptidase inhibitor activity involved in apoptotic process
  • ·negative regulation of apoptotic process
  • ·regulation of apoptotic process

Immune signalling

  • ·inflammatory response
  • ·regulation of inflammatory response
  • ·regulation of innate immune response

Metabolic enzyme activity

  • ·transferase activity
  • ·ubiquitin-protein transferase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Birinapant
Phase 2Inhibitor

cIAP1/cIAP2 inhibitor

Acts on a complex — shared with BIRC2 · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene BIRC3

Gene-level evidence surfaced through the gene BIRC3that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Crohn's Disease
0.67Moderately supported

Genetic evidence dominant · Open Targets 0.41

Leukemia, Lymphocytic, Chronic, B-Cell
0.48Limited support

Somatic mutation evidence dominant · Open Targets 0.45

Lymphoma, Mantle-Cell
0.41Limited support

Somatic mutation evidence dominant · Open Targets 0.38

Multiple Myeloma
0.41Limited support

Somatic mutation evidence dominant · Open Targets 0.37

Cutaneous melanoma
0.40Limited support

Somatic mutation evidence dominant · Open Targets 0.37

View evidence synthesis (5)
Crohn's DiseaseModerately supported
0.67
agreement 0.55–0.80
Genetic97%RNA expression2%Literature1%

Open Targets aggregate 0.41 · 3 independent evidence families

Leukemia, Lymphocytic, Chronic, B-CellLimited support
0.48
agreement 0.36–0.60
Somatic mutation68%Literature24%Clinical8%

Open Targets aggregate 0.45 · 3 independent evidence families

Lymphoma, Mantle-CellLimited support
0.41
agreement 0.25–0.57
Somatic mutation93%Literature7%

Open Targets aggregate 0.38 · 2 independent evidence families

Multiple MyelomaLimited support
0.41
agreement 0.25–0.57
Somatic mutation95%Literature6%

Open Targets aggregate 0.37 · 2 independent evidence families

Cutaneous melanomaLimited support
0.40
agreement 0.24–0.56
Somatic mutation99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Lymphocytic, Chronic, B-Cell0.45
Crohn's Disease0.41
Lymphoma, Mantle-Cell0.38
Multiple Myeloma0.37
Cutaneous melanoma0.37
Lymphoid neoplasm0.37
Skin squamous cell carcinoma0.37
Squamous cell lung carcinoma0.31
Carcinoma, Hepatocellular0.30

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (1)
BIRINAPANTPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Strong

Advanced Clinical and High-Quality Ligand support this modality.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Advanced ClinicalSM · High-Quality LigandSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

12

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)PHASE1

ACTIVE_NOT_RECRUITING · via Birinapant · NCT03803774

A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)PHASE1/PHASE2

WITHDRAWN · via Birinapant · NCT02756130

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid TumorsPHASE1/PHASE2

TERMINATED · via Birinapant · NCT02587962

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaPHASE2

TERMINATED · via Birinapant · NCT02147873

View all trials (8)
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine TherapyPHASE1/PHASE2

COMPLETED · via Birinapant · NCT01828346

Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary PeritonealPHASE2

TERMINATED · via Birinapant · NCT01681368

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic LeukemiaPHASE1/PHASE2

TERMINATED · via Birinapant · NCT01486784

A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid TumorsPHASE1/PHASE2

COMPLETED · via Birinapant · NCT01188499

An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersPHASE1

TERMINATED · via Birinapant · NCT04553692

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis BPHASE1

TERMINATED · via Birinapant · NCT02288208

A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerPHASE1

COMPLETED · via Birinapant · NCT01940172

A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or LymphomaPHASE1

COMPLETED · via Birinapant · NCT00993239

ClinicalTrials.gov via the drug-target graph.